Ferrari MD, Zuurbier KWM, Barash S, Ning X, et al. Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid. Headache 2022 Apr 6. doi: 10.1111/head.14294.
PMID: 35383922